ERLIN2

Erlin-2 · O94905 · ERLIN2 on Sugi Atlas →

0 patent compounds predicted against ERLIN2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ERLIN2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin PHASE2/PHASE3UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Investigator-initiated Clinical Trial of MIKE-1 PHASE1/PHASE2UNKNOWN
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Consequences of Mutations in the SPG7 Gene at the Heterozygous State nanCOMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
MEHMO Natural History and Biomarkers nanRECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
I-Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Early Check: Expanded Screening in Newborns nanENROLLING_BY_INVITATION
Genetic Variation in CLTCL1 and Whole-body Glucose Control nanCOMPLETED
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms nanCOMPLETED
Severe Insulin Resistance in Patients With Type 2 Diabetes nanCOMPLETED
Effect of Protein on Endoplasmic Reticulum Stress nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ERLIN2 binder may also engage these)

ProteinNameSimilarity
Q5R7C5 1.000 Q5R7C5 →
Q8BFZ9 1.000 Q8BFZ9 →
Q1RMU4 1.000 Q1RMU4 →
B5DEH2 1.000 B5DEH2 →
A3QK16 1.000 A3QK16 →
Q28J34 0.999 Q28J34 →
Q58EG2 0.998 Q58EG2 →
Q5XH03 0.997 Q5XH03 →
Q6DKC0 0.996 Q6DKC0 →
ERLIN1 Erlin-1 0.990 landscape →
Q5RCJ9 0.988 Q5RCJ9 →
Q28DX1 0.987 Q28DX1 →
Q91X78 0.982 Q91X78 →
P84173 0.959 P84173 →
PHB1 Prohibitin 1 0.956 landscape →
P67779 0.955 P67779 →
Q3T165 0.955 Q3T165 →
P67778 0.951 P67778 →
Q9CAR7 0.938 Q9CAR7 →
Q5R895 0.928 Q5R895 →
Q28943 0.928 Q28943 →
Q9SRH6 0.927 Q9SRH6 →
DPYD Dihydropyrimidine dehydrogenase [NADP(+)] 0.926 landscape →
P11497 0.925 P11497 →
B9N1F9 0.924 B9N1F9 →
Q5SWU9 0.923 Q5SWU9 →
Q5ZLA5 0.923 Q5ZLA5 →
O54734 0.923 O54734 →
Q28007 0.923 Q28007 →
B5DGH9 0.923 B5DGH9 →